# US 2023/0053748 A1 · Microbial combinations and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2023/0053748 A1 - Document ID: US20230053748A1 - Status: Published application - Kind: A1 - Application number: 17/880,923 - Filed: 2022-08-04 - Published: 2023-02-23 - Earliest claimed: 2020-02-06 - Applicants: Buzzelet Development and Technologies Ltd. - Inventors: AHARON EYAL; NOA RAZ - Web page: https://patentgrep.com/patent/US20230053748A1 ## CPC - A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics - A61K 31/015: carbocyclic - A61K 31/12: Ketones - A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol} - A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs - A61K 35/745: Bifidobacteria - A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/16: Anti-Parkinson drugs - A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract A method of treating a condition and/or a symptom associated with an effect of at least one element of the endocannabinoid system in an animal, the method including administering to the animal (i) a therapeutically effective amount of at least one microorganism and/or of a prebiotic thereof, where the microorganism is capable of modulating an effect of at least one element of the endocannabinoid system of the animal and (ii) a therapeutically effective amount of at least one compound capable of modulating an effect of at least one element of the endocannabinoid system of the animal. Further provided are compositions for use in such methods. ## Claims ### Claim 1 A method of treating a condition and/or a symptom associated with an effect of at least one element of the endocannabinoid system in an animal, the method comprising administering to said animal (i) a therapeutically effective amount of at least one microorganism and/or of a prebiotic thereof, wherein said microorganism is capable of modulating an effect of at least one element of the endocannabinoid system of said animal; and (ii) a therapeutically effective amount of at least one compound capable of modulating an effect of at least one element of the endocannabinoid system of said animal. ### Claim 2 (depends on 1) The method of claim 1, wherein said microorganism and said at least one compound are capable of modulating a same said at least one element of said endocannabinoid system of said animal. ### Claim 3 (depends on 1) The method of claim 1, wherein said microorganism is capable of modulating a first said element of said endocannabinoid system and said at least one compound is capable of modulating a second element of said endocannabinoid system, wherein said first element is different from said second element. ### Claim 4 (depends on 1) The method of claim 1, wherein said condition and/or symptom is associated with at least one selected from the group consisting of the gastrointestinal tract, adipose tissue, and the immune system. ### Claim 5 (depends on 1) The method of claim 1, wherein said condition and/or symptom is selected from the group consisting of migraine, fibromyalgia, irritable bowel diseases, diabetes, post-traumatic stress disorders, affective disorders, anorexia, motion sickness, multiple sclerosis, Parkinson disease, autism spectrum disorder, clinical deficiency of an endocannabinoid, visceral sensation, visceral pain, visceral motility disorder, gastrointestinal motility disorder, inflammation, metabolic disorder, insulin resistance and combinations thereof. ### Claim 6 (depends on 1) The method of claim 1, wherein said at least one element of the endocannabinoid system is selected from the group consisting of endocannabinoid receptors, endocannabinoids, endocannabinoids synthesizing enzymes, endocannabinoids degrading enzymes, and combinations thereof. ### Claim 7 (depends on 1) The method of claim 1, wherein said at least one microorganism modulates the expression of at least one selected from the group consisting of cannabinoid type 1 (CB1) receptors, cannabinoid type 2 (CB2) receptors, transient receptor potential (TRP) channels, Peroxisome proliferator-activated receptors (PPARs), anandamide, 2-Arachidonoylglycerol (2AG), fatty acid amide hydrolase (FAAH), N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), monoacylglycerol lipase (MAGL), diacylglycerol (DAG) lipases or combinations thereof. ### Claim 8 (depends on 1) The method of claim 1, wherein said at least one compound is selected from the group consisting of 2-linoleoyl-glycerol (2-Lino-Gl), 2-palmitoyl-glycerol (2-Palm-Gl), N-palmitoylethanolamide (PEA), N-oleoyl ethanolamine (OEA) and combination thereof. ### Claim 9 (depends on 1) The method of claim 1, wherein said treating induces the production of neurotransmitters and/or neuromodulators in the enteric nervous system. ### Claim 10 (depends on 1) The method of claim 1, wherein said at least one microorganism comprises a strain selected from the group consisting of Lactobacillus, Bifidobacterium, Prevotella, Bacteroides and combinations thereof. ### Claim 11 (depends on 1) The method of claim 1, wherein said administering said at least one microorganism comprises feeding said animal a food comprising a therapeutically effective amount of said microorganism and/or said prebiotic. ### Claim 12 (depends on 1) The method of claim 1, wherein said administering said at least one microorganism is conducted prior to or simultaneously with said administering said at least one compound. ### Claim 13 (depends on 1) The method of claim 1, comprising multiple administrations of said at least one microorganism and/or said prebiotic and multiple administrations of said at least one compound. ### Claim 14 (depends on 1) The method of claim 1, wherein said at least one microorganism and/or said prebiotic and said at least one compound are provided as a kit. ### Claim 15 A composition comprising (i) a therapeutically effective amount of at least one microorganism and/or of a prebiotic thereof, wherein said at least one microorganism is capable of modulating an effect of at least one element of the endocannabinoid system, and (ii) a therapeutically effective amount of at least one compound capable of modulating an effect of at least one element of the endocannabinoid system. ### Claim 16 (depends on 15) The composition of claim 15, wherein said compound is an allocentric modulator of a gastrointestinal tract endocannabinoid receptor. ### Claim 17 (depends on 15) An animal food comprising the composition of claim 15 and at least one food ingredient.